Transfer process of marketing authorisations for 14 Rx brands to begin in October
Sun Pharma announced the initiation of a phased transfer of manufacturing and marketing rights in Japan for 14 long-listed/ established prescription brands acquired from Novartis. These 14 prescription brands are The 14 brands are Parlodel, Lamisil, Apresoline, Zaditen, Symmetrel, Cibacen, Tegretol, Pursennid, Lioresal, Lopresor, Ternelin, Ludiomil, and Lochol. They were acquired by the company earlier this year and will be transferred from Novartis Pharma KK to Sun Pharma’s subsidiary in Japan beginning October 2016.
Sun Pharma has also signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands. Under this alliance, following the transfer of manufacturing and marketing rights to Sun Pharma’s subsidiary in Japan, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals.
According to Isao Muramatsu, President & Representative Director, Sun Pharma Japan, Sun Pharma, “Through this alliance we have the opportunity to leverage Mitsubishi Tanabe Pharma Corporation’s specialised expertise to create a strong business foundation for us in Japan. Sun Pharma will focus on expanding its sales channels in Japan’s pharma market while continuing to ensure a stable supply of medicines and healthcare information.”
EP News Bureau – Mumbai